The gene-editing approach uses prime editors and evolved enzymes called recombinases, and could pave the way to effective one-size-fits-all gene therapies for diseases such as cystic fibrosis.
Scientists at St. Jude Children’s Research Hospital and the Broad Institute of MIT and Harvard showed how prime editing can correct mutations that cause sickle cell disease in a potentially curative approach.
A one-time genome-editing treatment restores motor function and extends lifespan in an animal model of a neuromuscular disease that is the leading genetic cause of infant mortality.
New method finds compounds that bind and inhibit individual members of a family of key regulatory proteins, called cyclophilins, that have been difficult to target selectively.